Sanara MedTech's BIASURGE awarded Vizient innovative technology contract

Sanara MedTech said Vizient awarded its BIASURGE Advanced Surgical Solution an Innovative Technology contract that provides Vizient members access under contracted pricing and pre-negotiated terms effective January 1, 2026; the article is based on a company press release.

Sanara MedTech announced that its BIASURGE Advanced Surgical Solution has been awarded an Innovative Technology contract by Vizient. The award was recommended by hospital experts on Vizient's client-led councils. The agreement is reported to give Vizient's network access to BIASURGE under contracted pricing and pre-negotiated terms. The company provided the details in a press release. Reported details: - The contract was awarded by Vizient Inc., which represents academic medical centers, pediatric facilities, community hospitals and integrated health delivery networks and reports more than $156 billion in annual purchasing volume. - The agreement is reported to be effective January 1, 2026, and will make BIASURGE available to Vizient members at contracted pricing and pre-negotiated terms. - Sanara MedTech describes BIASURGE as a no-rinse irrigation solution designed for mechanical cleansing and removal of debris, with an antimicrobial preservative and a proprietary formulation optimized for pH, viscosity and osmolality; it is suitable for use with irrigation systems. - The contract award and related details were reported in a company press release and summarized in the article. - Separately, Sanara MedTech reported Q3 2025 net revenue of $26.3 million, a 22% year-over-year increase, and announced plans to seek U.S. launch of its OsStic Synthetic Injectable Structural Bio‑Adhesive in the first quarter of 2027 pending FDA clearance. Summary: The Vizient contract will make BIASURGE available across Vizient's member network under the reported terms beginning January 1, 2026. The company also reported higher Q3 2025 revenue and has announced plans to seek FDA clearance for OsStic with a planned U.S. launch in the first quarter of 2027, pending that clearance.